Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
E
Eriko Tokunaga
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
361
Papers
13.4K
Citations
49
h-index
131
i10-index
Eriko Tokunaga is an academic researcher from National Hospital Organization Kyushu Cancer Center. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 49, co-authored 307 publications.
ORCID: 0000-0002-1640-5315Papers by this author
worksVimentin as a poor prognostic factor for triple-negative breast cancer
2013 · Journal of Cancer Research and Clinical Oncology · 182 citations
https://doi.org/10.1007/s00432-013-1376-6
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · The Lancet Oncology · 120 citations
https://doi.org/10.1016/s1470-2045(17)30715-5
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
2024 · New England Journal of Medicine · 118 citations
https://doi.org/10.1056/nejmoa2410858
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer
2006 · European Journal of Cancer · 117 citations
https://doi.org/10.1016/j.ejca.2005.11.025
Trastuzumab and breast cancer: developments and current status
2006 · International Journal of Clinical Oncology · 93 citations
https://doi.org/10.1007/s10147-006-0575-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat